Cargando…

Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice

SIMPLE SUMMARY: Although atezolizumab plus bevacizumab combination therapy was approved in September 2020 as the first immune-combined therapy for hepatocellular carcinoma, the efficacy and safety of this therapy are unclear in real-world practice. This study investigated the early antitumor effects...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ando, Yuwa, Kawaoka, Tomokazu, Kosaka, Masanari, Shirane, Yuki, Johira, Yusuke, Miura, Ryoichi, Murakami, Serami, Yano, Shigeki, Amioka, Kei, Naruto, Kensuke, Kosaka, Yumi, Uchikawa, Shinsuke, Kodama, Kenichiro, Fujino, Hatsue, Nakahara, Takashi, Ono, Atsushi, Murakami, Eisuke, Yamauchi, Masami, Okamoto, Wataru, Takahashi, Shoichi, Imamura, Michio, Chayama, Kazuaki, Aikata, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394131/ https://www.ncbi.nlm.nih.gov/pubmed/34439111 http://dx.doi.org/10.3390/cancers13163958

Ejemplares similares

Risk Factors for Early Onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
por: Ando, Yuwa, et al.
Publicado: (2022)

Successful Lenvatinib Re-challenge following Atezolizumab Plus Bevacizumab Combination Therapy Failure for Unresectable Hepatocellular Carcinoma
por: Kosaka, Yumi, et al.
Publicado: (2022)

Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab
por: Yano, Shigeki, et al.
Publicado: (2021)

Benign Recurrent Intrahepatic Cholestasis Type 1 with Novel Nonsense Mutations in the ATP8B1 Gene
por: Miura, Ryoichi, et al.
Publicado: (2022)

The importance of body composition assessment for patients with advanced hepatocellular carcinoma by bioelectrical impedance analysis in lenvatinib treatment
por: Yamaoka, Kenji, et al.
Publicado: (2022)

Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
por: Yano, Shigeki, et al.
Publicado: (2023)

Impact and usefulness of the transition to the new MAFLD classification for non-B, non-C HCC: a retrospective cohort study
por: Johira, Yusuke, et al.
Publicado: (2023)

Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma
por: Amioka, Kei, et al.
Publicado: (2022)

Evaluation of Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma Using the Combination of Response Evaluation Criteria in Solid Tumors and Alpha-Fetoprotein
por: Kinami, Takahiro, et al.
Publicado: (2023)

Hepatic venous pressure gradient after balloon-occluded retrograde transvenous obliteration and liver stiffness measurement predict the prognosis of patients with gastric varices
por: Shirane, Yuki, et al.
Publicado: (2022)

Effectiveness of Repeated Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma—Consideration of the Locations of Target Lesions
por: Yano, Shigeki, et al.
Publicado: (2023)

A case of acute liver failure with echovirus infection diagnosed by a multi-virus real-time PCR system
por: Yoshikawa, Yuki, et al.
Publicado: (2021)

Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study
por: Nagaoki, Yuko, et al.
Publicado: (2021)

Efficacy and safety of chemoradiation therapy using one-shot cisplatin via hepatic arterial infusion for advanced hepatocellular carcinoma with major macrovascular invasion: a single-arm retrospective cohort study
por: Naruto, Kensuke, et al.
Publicado: (2022)

Analysis of Lenvatinib’s Efficacy against Intermediate-Stage Unresectable Hepatocellular Carcinoma
por: Amioka, Kei, et al.
Publicado: (2022)

Complete Response for Advanced Hepatocellular Carcinoma by Conversion Surgery Therapy Following a Good Response of Regorafenib Despite Rapid Progressive Disease with Sorafenib
por: Yamaoka, Kenji, et al.
Publicado: (2021)

Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib
por: Fujii, Yasutoshi, et al.
Publicado: (2021)

Association of Hepatobiliary Phase of Gadoxetic-Acid-Enhanced MRI Imaging with Immune Microenvironment and Response to Atezolizumab Plus Bevacizumab Treatment
por: Tamura, Yosuke, et al.
Publicado: (2023)

Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis
por: Fujino, Hatsue, et al.
Publicado: (2019)

Early experience of seven hepatocellular carcinoma cases treated with regorafenib
por: Uchikawa, Shinsuke, et al.
Publicado: (2018)

Early changes in ammonia levels and liver function in patients with advanced hepatocellular carcinoma treated by lenvatinib therapy
por: Ohya, Kazuki, et al.
Publicado: (2019)

Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinoma
por: Yamauchi, Masami, et al.
Publicado: (2023)

Levocarnitine Use Is Associated With Improvement in Sarcopenia in Patients With Liver Cirrhosis
por: Hiramatsu, Akira, et al.
Publicado: (2019)

Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma
por: Yamauchi, Masami, et al.
Publicado: (2020)

Three Children Treated with Direct-acting Antivirals for Chronic Hepatitis C Virus Genotype 1b Infection
por: Ohya, Kazuki, et al.
Publicado: (2019)

Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib
por: Ono, Atsushi, et al.
Publicado: (2020)

Liver fibrosis assessments using FibroScan, virtual-touch tissue quantification, the FIB-4 index, and mac-2 binding protein glycosylation isomer levels compared with pathological findings of liver resection specimens in patients with hepatitis C infection
por: Ueda, Naoyuki, et al.
Publicado: (2020)

In vitro analysis of hepatic stellate cell activation influenced by transmembrane 6 superfamily 2 polymorphism
por: Liu, Songyao, et al.
Publicado: (2021)

Therapeutic effects of sleeve gastrectomy for non-alcoholic steatohepatitis estimated by paired liver biopsy in morbidly obese Japanese patients
por: Murakami, Eisuke, et al.
Publicado: (2021)

Efficacy of Lusutrombopag for Thrombocytopenia in Patients with Chronic Liver Disease Scheduled to Undergo Invasive Procedures
por: Nishida, Yuno, et al.
Publicado: (2020)

Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review
por: Ahmed, Faiza, et al.
Publicado: (2021)

Significance of liver resection for intermediate stage hepatocellular carcinoma according to subclassification
por: Yamamoto, Masateru, et al.
Publicado: (2021)

Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial
por: Hatooka, Masahiro, et al.
Publicado: (2018)

Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter Analysis
por: Hiraoka, Atsushi, et al.
Publicado: (2022)

Impact of skeletal muscle volume on patients with BCLC stage‐B hepatocellular carcinoma undergoing sorafenib therapy
por: Saeki, Issei, et al.
Publicado: (2023)

Does first‐line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib
por: Hiraoka, Atsushi, et al.
Publicado: (2022)

Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
por: Tada, Toshifumi, et al.
Publicado: (2022)

The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy
por: Nagaoki, Yuko, et al.
Publicado: (2017)

Skeletal Muscle Volume Is an Independent Predictor of Survival after Sorafenib Treatment Failure for Hepatocellular Carcinoma
por: Saeki, Issei, et al.
Publicado: (2021)

Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience
por: Hiraoka, Atsushi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6r60th9m0dmhg0crj5d6v0v9jk